Lojong vs Isomorphic Labs

Lojong's feature set is built entirely for individual wellbeing: hundreds of guided meditations in Brazilian Portuguese, structured programs for anxiety, sleep, stress, self-esteem, relationships and focus, complete tracks like 'Acolhendo a Ansiedade' (18 practices) and 'Primeiros Passos' (21 practices), sleep stories and relaxing sounds, guided breathing, yoga and movement practices, an emotional diary, stats, a free-meditation timer, offline mode and daily inspirational quotes. The only integration listed is Apple Watch. Isomorphic Labs operates in a completely different universe: a Drug Design Engine for generative molecule design, predictive and generative AI models for drug discovery, simulation of drug behavior, end-to-end research collaborations from target identification through lead optimization, a bioresilience framework for biological threats, and an interdisciplinary team of drug-discovery experts and ML specialists. Its recent Series B and Johnson & Johnson collaboration show where the effort goes — scaling AI drug design, not shipping a consumer app. There is zero feature overlap. Lojong sells convenience and emotional relief to a phone user; Isomorphic Labs sells scientific acceleration to enterprises with deep pipelines and budgets.

Lojong uses a freemium model: a free tier with core meditations and a paid subscription unlocking the full library of programs and tracks. Exact monthly and annual figures are not in the data provided, so check the app store listing for current pricing. For a consumer wellness app, this is a low-friction, cancel-anytime purchase. Isomorphic Labs is listed as 'contact' — there is no published price, no self-serve plan and no consumer option. Its economics are partnership-based: long-term research collaborations with large pharma, typically spanning target identification to lead optimization, funded at enterprise scale and reinforced by a Series B investment round announced in May 2026. A buyer comparing the two would be comparing a $5–$15-ish monthly app subscription against a multi-year, multi-million-dollar R&D relationship — there is no meaningful price comparison to make. Budget-wise these belong to different worlds, and neither pricing model is a substitute for the other.